Zura Bio Ltd

Zura Bio Ltd (Nasdaq: ZURA) is a clinical-stage biopharmaceutical company focused on immunology that entered the public markets through its business combination with JATT Ventures Corp, a blank check company sponsored by JATT Ventures Pte. Ltd. that completed its IPO in 2021. The January 19, 2023 Form 8-K filing with the SEC marks the closing of that merger, at which point the combined entity began trading on Nasdaq under the ZURA ticker. Zura Bio's pipeline targets immune-mediated conditions including alopecia areata and atopic dermatitis, positioning the company within the clinical-stage biopharma sector. For comprehensive SPAC filing histories, sponsor profiles, and deal analytics on ZURA and the broader SPAC market, sign up for SpacDesk at spacdesk.com.